Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

Johnson & Johnson and Protagonist Therapeutics announced positive Phase III results for icotrokinra, an oral IL-23 targeting ...

University of Copenhagen researchers have developed a prototype patch for treating plaque psoriasis, which may simplify ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Reviewed by Lexie CornerNov 13 2024 According to a study published in Biomaterials Advances, scientists at the University of ...

Johnson & Johnson's oral drug for a type of skin condition met the main goals of achieving clear or almost clear skin and ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...